Is There a Normal Microbiota in the Heart?
No, the healthy heart does not harbor a normal resident microbiota—it is a sterile organ under physiological conditions. The presence of microorganisms in cardiac tissue represents pathological infection, most notably infective endocarditis, rather than commensal colonization 1, 2, 3.
Understanding Cardiac Microbiology
The Heart as a Sterile Organ
- The cardiovascular system, including cardiac valves and myocardium, remains sterile in healthy individuals 4.
- Microorganisms detected in cardiac tissue invariably indicate infection requiring antimicrobial therapy 3.
- The concept of a "cardiac microbiome" analogous to gut microbiota does not exist in current medical literature or guidelines 1, 2, 5.
Pathological Microbial Presence: Infective Endocarditis
When bacteria colonize cardiac structures, this represents infective endocarditis—a serious illness with significant morbidity and mortality 2, 6.
The pathophysiology involves:
- Endothelial damage leading to platelet-fibrin deposition forming nonbacterial thrombotic lesions 1, 7.
- During bacteremia, organisms adhere to these lesions and multiply within the platelet-fibrin complex, creating infective vegetations 6, 7.
- Valvular abnormalities with high-velocity jets damage endothelium, predisposing to bacterial colonization 1, 2.
Common Causative Organisms in Cardiac Infection
The majority (80%) of infective endocarditis cases are caused by streptococcal and staphylococcal species 5:
- Viridans streptococci and Streptococcus bovis are typical organisms from oral/GI sources 5.
- Staphylococcus aureus causes 80% of tricuspid valve infections and is frequent in IV drug users and diabetics 5.
- Enterococcus faecalis and E. faecium account for 90% of enterococcal endocarditis, associated with GU/GI manipulation 5.
- HACEK organisms (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella) are less common 3, 8.
- Gram-negative bacilli (Enterobacteriaceae, Pseudomonas) are rare (1.8-2.1% of cases) 3, 8.
Systematic Reviews Correlating Microbiota with Cardiac Pathologies
Gut-Heart Axis: Indirect Microbial Influence
While the heart itself has no resident microbiota, systematic reviews have established that gut microbial dysbiosis correlates with cardiovascular diseases through metabolic pathways 9, 10, 11, 12.
Key Findings from Systematic Reviews:
Coronary Heart Disease (CHD):
- A 2021 systematic review of 16 cohort studies (2,210 patients) identified specific gut microbiota associated with CHD 9.
- Bacteroides and Prevotella were commonly identified in fecal samples of CHD patients across nine articles 9.
- Firmicutes were commonly identified in seven articles 9.
- Notably, Veillonella, Proteobacteria, and Streptococcus were found in both atherosclerotic plaques and gut samples 9.
- Clostridium was identified in both blood and fecal samples of CHD patients 9.
Heart Failure:
- A 2023 systematic review of 10 articles demonstrated significant gut microbiome compositional differences in heart failure patients 10.
- Increased relative abundance of Ruminococcus gnavus, Escherichia-Shigella, Streptococcus sp, Veillonella sp, and Actinobacteria 10.
- Relative depletion of Eubacterium, Prevotella, Faecalibacterium, SMB53, and Megamonas 10.
- Composition varied by age, heart failure stage, and decompensation level but remained unaltered with ejection fraction 10.
Mechanistic Pathways:
These reviews identified specific metaorganismal pathways linking gut microbiota to cardiovascular disease 11, 12, 13:
- Trimethylamine N-oxide (TMAO) pathway: gut bacteria metabolize dietary choline/carnitine to TMA, which is oxidized to TMAO in the liver, promoting atherosclerosis 12, 13.
- Phenylacetylglutamine: a gut microbiota-dependent metabolite that interacts with adrenergic receptors to promote adverse cardiovascular phenotypes 12.
- Short-chain fatty acids (SCFAs): produced by gut bacteria, with protective cardiovascular effects 11, 12, 13.
- Secondary bile acids: microbial biotransformation products affecting cardiovascular risk 12, 13.
- Lipopolysaccharide (LPS) biosynthesis: increased in heart failure, contributing to inflammation 10.
Important Distinction
It is critical to distinguish between:
- Direct cardiac infection (infective endocarditis)—where specific pathogens invade sterile cardiac tissue requiring antibiotics and often surgery 1, 2, 3.
- Indirect gut microbiota influence—where distant gut microbial communities affect cardiovascular health through circulating metabolites 9, 10, 11, 12, 13.
The systematic reviews address the latter phenomenon, not a resident cardiac microbiome.
Clinical Implications
The gut-heart axis represents a potential therapeutic target 10, 12, 13:
- Biomarkers like TMAO and phenylacetylglutamine show promise for cardiovascular risk stratification 12, 13.
- Dietary interventions, probiotics, and microbiome-targeted therapies are under investigation 11, 12.
- Population-specific features (diet, genetics, medications) influence these associations, requiring personalized approaches 13.